However, studies evaluating the metastasis of chRCC revealed that TP53 mutations, DNA hypermethylation, imbalanced chromosomal duplication, PTEN mutations, cyclin dependent kinase inhibitor 2A (CDKN2A) mutations have been coupled with high-risk features and poor survival [22]. This evidence concerns the gene TP53 and chromophobe renal cell carcinoma.